Company news

Seres Therapeutics, Inc. news in 2021

Seres Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

December 15, 2021

Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)

November 29, 2021

Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 9, 2021

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 9, 2021

Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021

October 1, 2021

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

September 14, 2021

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

August 2, 2021

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

July 21, 2021

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

June 30, 2021

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

June 9, 2021

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

May 31, 2021

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development

May 19, 2021

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

May 3, 2021

Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

March 7, 2021

Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

March 1, 2021

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

March 1, 2021

Calls in 2021

Decks in 2021